2. Academic Validation
  3. Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

  • Nat Commun. 2025 Nov 18;16(1):10096. doi: 10.1038/s41467-025-65056-9.
Chuanyu Tang 1 2 3 4 5 6,  Cheng He 1 2 3 4,  Decheng Wang 7,  Jie Guo 1 2 3 4,  Xiangyi Yin 1 2 3 4,  Hanjie Ye 1 2 3 4,  Lei Wu 8,  Yuling Zhang 5 6,  Silue Zeng 1 2 3 4 5 6,  Xiaojun Zeng 1 2 3 4,  Chengbo Liu 9 10,  Jingqin Chen 11 12,  Chihua Fang 13 14 15 16
Affiliations

Affiliations

  • 1 Department of Hepatobiliary Surgery I, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
  • 2 Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou, China.
  • 3 National Engineering Research Center of Innovation and Application of Minimally Invasive Instruments - South China Institute, Guangzhou, China.
  • 4 Digital Intelligent Minimally Invasive Surgery Institute, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
  • 5 Research Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • 6 State Key Laboratory of Biomedical Imaging Science and System, Shenzhen, China.
  • 7 Microbiome Medicine Center, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
  • 8 Department of Neurology, Guangdong Second Provincial General Hospital, Jinan University, Guangzhou, China.
  • 9 Research Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. [email protected].
  • 10 State Key Laboratory of Biomedical Imaging Science and System, Shenzhen, China. [email protected].
  • 11 Research Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. [email protected].
  • 12 State Key Laboratory of Biomedical Imaging Science and System, Shenzhen, China. [email protected].
  • 13 Department of Hepatobiliary Surgery I, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China. [email protected].
  • 14 Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou, China. [email protected].
  • 15 National Engineering Research Center of Innovation and Application of Minimally Invasive Instruments - South China Institute, Guangzhou, China. [email protected].
  • 16 Digital Intelligent Minimally Invasive Surgery Institute, Zhujiang Hospital, Southern Medical University, Guangzhou, China. [email protected].
PMID: 41253833 DOI: 10.1038/s41467-025-65056-9
Abstract

The prevalence of immunosuppressive, tumor-associated macrophages (TAM) in the tumor microenvironment of hepatocellular carcinoma (HCC) compromises the efficacy of sorafenib (SF)-based, ferroptosis-inducing systemic therapies. Increasing the susceptibility of tumor cells and TAMs to Ferroptosis represents a promising breakthrough in improving the therapeutic outcomes of SF. Here, we show that the upregulation of Ferroptosis suppressor protein 1 (FSP1) counteracts SF-induced Ferroptosis independently of Glutathione Peroxidase 4 (GPX4) and correlates with increased immunosuppressive TAM infiltration and unfavorable prognosis. In preclinical HCC mouse models, biomimetic nanoparticles, co-loaded with SF and the FSP1 inhibitor viFSP1 and designed to simultaneously target tumor cells and immunosuppressive TAMs, enhance Ferroptosis in both cell types, promoting antigen presentation and cytotoxic T cell infiltration. Furthermore, combinatorial treatment with an anti-PD-L1 antibody suppresses metastasis and tumor recurrence. Thus, our nanoparticle-based dual-target strategy induces synergistic ferroptosis-immunotherapy in HCC, and represents a promising strategy to sensitize tumors to SF treatment, driving the remodeling of the immunosuppressive tumor microenvironment.

Figures
Products